Inhibition of α-synuclein Cell-cell Transmission by NMDAR Blocker, Memantine

Last updated: June 29, 2020
Sponsor: Wayne State University
Overall Status: Active - Recruiting

Phase

3

Condition

N/A

Treatment

N/A

Clinical Study ID

NCT03858270
09282018
  • Ages 45-85
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Lewy Body Dementia (LBD), is the second most common form of dementia after Alzheimer's Disease. Dementia is defined as a serious loss in cognitive ability due to damages or disease in the brain beyond what is normal aging. With Lewy Body Dementia, protein deposits, or Lewy Bodies, accumulate in nerve cells throughout the brain, affecting motor control, memory and thinking. LBD can also form with the progression of Parkinson's disease (PD). PD is a degenerative nervous system disorder that affects movement ability. Using more sensitive MRI imaging techniques the investigators are attempting to see if disease progression can be monitored more closely. At the same time, the study medication Memantine will be compared to a placebo to determine if it can be used to slow the progression of PD. The purpose of this study is to assess if disease progression can be better monitored through brain imaging and if Memantine will help slow disease progression.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Diagnosed with idiopathic PD for at least 2 or more years

  2. 45 to 85 years of age

  3. Have been on stable doses of anti-Parkinson medication

  4. Able to give informed consent

  5. Able to undergo brain MRI

  6. Unilateral symptoms

  7. A score of 26 or greater on the Montreal Cognitive Assessment (MOCA), a measure of apatients short-term memory recall, the ability to determine visual-spatialrelationships of objects, attention, concentration, working memory, language andorientation to time and place

  8. Use of one method of medically approved contraceptive

Exclusion

Exclusion Criteria:

  1. History of any surgical intervention for treating PD (i.e. deep brain stimulation)

  2. Extreme physical disability

  3. History or current diagnosis of unstable psychiatric condition

  4. Presence of dementia or any other condition that prevents the ability of theparticipant to provide fully informed consent

  5. Other brain disease

  6. Treatment with Memantine 30 days prior to baseline

  7. Females who are pregnant or nursing

  8. Presence of interacting medications with Memantine or co-morbid medical conditionsthat may be exacerbated by this agent

  9. Moderately significant drug interactions with Dextromethorphan, Amantadine, SodiumBicarbonate, and Acetazolamide

  10. Previous Allergic reaction to Memantine

  11. Any genetic form of PD

Study Design

Total Participants: 50
Study Start date:
April 01, 2019
Estimated Completion Date:
July 01, 2023

Connect with a study center

  • Wayne State University

    Detroit, Michigan 48201
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.